Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

344 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.
Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Pitt B, et al. Among authors: riegger g. Lancet. 2000 May 6;355(9215):1582-7. doi: 10.1016/s0140-6736(00)02213-3. Lancet. 2000. PMID: 10821361 Clinical Trial.
Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II).
Konstam MA, Neaton JD, Poole-Wilson PA, Pitt B, Segal R, Sharma D, Dasbach EJ, Carides GW, Dickstein K, Riegger G, Camm AJ, Martinez FA, Bradstreet DC, Ikeda LS, Santoro EP; ELITE II Investigators. Konstam MA, et al. Among authors: riegger g. Am Heart J. 2005 Jul;150(1):123-31. doi: 10.1016/j.ahj.2004.10.035. Am Heart J. 2005. PMID: 16084158 Clinical Trial.
Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study--ELITE II.
Pitt B, Poole-Wilson P, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Pitt B, et al. Among authors: riegger g. J Card Fail. 1999 Jun;5(2):146-54. doi: 10.1016/s1071-9164(99)90037-4. J Card Fail. 1999. PMID: 10404354 Clinical Trial.
COX-2 inhibitors and risk of heart failure.
Kammerl MC, Debler J, Riegger GA, Krämer BK. Kammerl MC, et al. Lancet. 2004 Oct 23-29;364(9444):1486-7; author reply 1487. doi: 10.1016/S0140-6736(04)17265-6. Lancet. 2004. PMID: 15500886 No abstract available.
A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure.
Dargie HJ, Hildebrandt PR, Riegger GA, McMurray JJ, McMorn SO, Roberts JN, Zambanini A, Wilding JP. Dargie HJ, et al. J Am Coll Cardiol. 2007 Apr 24;49(16):1696-704. doi: 10.1016/j.jacc.2006.10.077. Epub 2007 Apr 6. J Am Coll Cardiol. 2007. PMID: 17448371 Free article. Clinical Trial.
Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).
Komajda M, Lutiger B, Madeira H, Thygesen K, Bobbio M, Hildebrandt P, Jaarsma W, Riegger G, Rydén L, Scherhag A, Soler-Soler J, Remme WJ; CARMEN investigators and co-ordinators. Komajda M, et al. Among authors: riegger g. Eur J Heart Fail. 2004 Jun;6(4):467-75. doi: 10.1016/j.ejheart.2003.12.019. Eur J Heart Fail. 2004. PMID: 15182773 Free article. Clinical Trial.
344 results